http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Fundamentals of early clinical drug development
Reflections on process research II -- Development and scale-up of a heterocyclic cross-coupling for the synthesis of 5-(2-(3-methyl-3H-imidazol-4-yl)thieno(3,2-b)pyridine-7-yl)amino-2-methyl-1H-indole -- Large-scale enantioselective preparation of 2E,7E, 5S,6R, 5-hydroxy-6-methyl-8-phenyl-octa-2,7-dienoic acid, a key fragment for the formal total synthesis of the anti-tumor agent cryptophycin 52 -- Efforts toward a commercially viable route and process to the synthesis of HIV PI GW640385X -- Development of an asymmetric synthesis of ABT-100 -- Asymmetric hydrogenation : a new route to pregabalin -- Responsibilities of the process chemist : beyond synthetic organic chemistry -- Outsourcing : the challenge of science, speed, and quality -- Automation and the changing face of process research in the pharmaceutical industry -- Large scale synthesis : an engineering perspective -- Synthesis and application of radioisotopes in pharmaceutical research and development -- Selection of the drug form in exploratory development -- Strategies to achieve particle size of active pharmaceutical ingredients -- Challenges in early formulation : turning drug substance into drug product -- Intellectual property and early development.
edited by Ahmed F. Abdel-Magid and Stéphane Caron.
Includes bibliographical references and index.